Owlet, Inc. announced a strategic partnership with PromptCare, a national respiratory services and durable medical equipment provider, to broaden the distribution of its FDA‑cleared BabySat pulse oximeter for high‑risk infants. The deal extends Owlet’s reach into clinical and DME channels across key U.S. regions, positioning the company to capture a growing market for at‑home monitoring of high‑risk newborns.
The partnership leverages PromptCare’s network of respiratory specialists, pediatric hospitals, and home‑care agencies, allowing BabySat to be prescribed and delivered through established clinical pathways. By integrating BabySat into PromptCare’s product portfolio, Owlet can tap into a patient base that relies on insurance‑supported DME services, potentially accelerating prescription volumes and revenue growth.
Owlet’s recent financial performance underscores the strategic importance of the partnership. In Q3 2025, the company generated $32.0 million in revenue, up 44.6% from $22.0 million in Q3 2024, and posted a net income of $4.1 million versus a $5.6 million loss in the prior year. Full‑year 2025 guidance now projects revenue between $103 million and $106 million, representing 32%–36% growth year‑over‑year. The partnership is expected to contribute incremental unit shipments and strengthen Owlet’s clinical distribution model, supporting the company’s broader growth trajectory.
Jonathan Harris, President and CEO of Owlet, said the collaboration “represents a meaningful step forward in our DME expansion strategy. PromptCare’s deep experience in pediatric respiratory care and strong relationships with children’s hospitals make them an ideal partner as we continue to scale our clinical distribution model and make an impact where it matters most.” Matt Keppler, President of Respiratory at PromptCare, added that Owlet’s technology complements their offerings and will enhance patient care in the home setting.
The deal also signals a shift from Owlet’s consumer‑direct sales model toward a hybrid approach that blends direct‑to‑parent and clinical distribution. By accessing PromptCare’s established billing and reimbursement infrastructure, Owlet can reduce sales cycle times and improve market penetration, addressing a key headwind in the high‑risk infant monitoring segment.
While the partnership does not immediately alter Owlet’s financial statements, it positions the company to capture a larger share of the growing at‑home monitoring market, potentially improving revenue mix and providing a more resilient distribution base. Investors will likely view the collaboration as a strategic investment in long‑term growth and a hedge against the competitive pressures in the consumer‑direct space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.